36 GLP-1 Usage Statistics 2027: How Many Americans Take a GLP-1, Who They Are and Who Pays

Explore the latest U.S. GLP-1 usage statistics, including adoption rates, women's treatment patterns, affordability, insurance coverage, side effects, and long-term treatment persistence.

Majesta HealthReviewed by Ksenia Petrushkina, PA-C
Published Updated Reviewed 24 min read

Explore the latest U.S. GLP-1 usage statistics, including adoption rates, women's treatment patterns, affordability, insurance coverage, side effects, and long-term treatment persistence.

GLP-1 medications have grown from a niche diabetes treatment category to an increasingly common option for weight management. Behind these numbers lies a clear pattern: women represent a substantial share of users, affordability remains a barrier, and many users want better support during treatment. For women seeking doctor-guided GLP-1 weight management with straightforward pricing and ongoing care, these statistics reveal both the opportunity and the gaps in the current market.

This article brings together 36 U.S. statistics on GLP-1 medications, including how many people take them, who uses them, what they pay, and how long they remain on treatment. Each figure identifies the relevant population, measurement period, and original source.

Key Takeaways

  • GLP-1 adoption continues growing: 11% of U.S. adults currently use GLP-1 medications for weight loss, up from 3% in 2024.
  • Women lead adoption in certain groups: Among adults aged 30 to 49, 15.1% of women have tried GLP-1 medications, compared with 7.2% of men.
  • Affordability remains a major obstacle: 56% of GLP-1 users report difficulty affording their medications, including 55% of those with insurance coverage.
  • Compounded medications represent a measurable share: 18% of current users taking GLP-1s for weight loss report using compounded or custom-mixed preparations.
  • Wellness support remains fragmented: Roughly 85% of current users in PwC's survey say companies are falling short in meeting their needs.
  • Long-term persistence varies substantially: Only 14.8% of patients in one commercially insured obesity-treatment cohort remained on treatment at two years, while more recent cohorts showed higher one-year persistence.

GLP-1 usage at a glance

The most commonly cited GLP-1 usage statistics come from different surveys and patient populations. The following table summarizes the major findings before examining each in detail.

QuestionFindingPopulation and period
How many adults currently take GLP-1s for any reason?12%U.S. adults, KFF, fall 2025
How many take GLP-1s for weight loss?11%U.S. adults, Gallup, mid-2026
How many adults have ever used them?18% for any reason; 15% for weight lossKFF, 2025; Gallup, 2026
How many households include a current user?21%U.S. households, PwC/Numerator, May 2026
Which age group has the highest current usage?Ages 50–64: 22%KFF, fall 2025
Are women more likely to have used them?15.1% of women versus 7.2% of men aged 30–49RAND, spring 2025
How many users experience affordability difficulties?56%Adults who ever used GLP-1s, KFF, fall 2025
How many weight-loss users report compounded medications?18%Current weight-loss users, Gallup, 2026
How many remain on treatment?14.8% at two years in one 2021 cohortCommercially insured obesity-treatment patients, Prime Therapeutics

Sources: *KFF,* *Gallup,* *RAND,* *PwC, and* Prime Therapeutics*. These figures measure different populations and should not be directly compared.*

Current GLP-1 Adoption and Usage Rates

The adoption curve for GLP-1 medications has accelerated dramatically. What was once a treatment reserved for specific diabetes management has become increasingly common across multiple patient populations.

1. 11% of U.S. adults currently take GLP-1s for weight loss

According to Gallup's National Health and Well-Being Index, 11% of U.S. adults currently take GLP-1 medications specifically for weight loss purposes in 2026, up from 3% in 2024.

The percentage also increased from 8% in 2025, according to Gallup's nationally representative surveys.

These figures measure weight-loss medication use specifically, rather than all prescriptions for diabetes and other medical conditions.

2. 15% of U.S. adults have ever used GLP-1s for weight loss

Beyond current users, 15% of adults report having used GLP-1 medications for weight loss at some point, representing a nine-percentage-point increase since 2024.

Gallup reported that 6% had ever used these medications in 2024, increasing to 12% in 2025.

The lifetime-use figure includes former users as well as people currently taking the medications, distinguishing it from current treatment rates.

3. 12% of U.S. adults currently use GLP-1s for various conditions

When including all indications, 12% of U.S. adults reported taking a GLP-1 for weight loss, diabetes, or other medical conditions in KFF's November 2025 survey.

KFF also found that 18% of adults had ever used these medications.

Unlike Gallup's weight-loss-specific figures, this survey includes medications taken for diabetes and other health conditions.

4. 11.8% of adults reported ever using GLP-1 agonists in 2025

RAND research found that 11.8% of adults reported having used GLP-1 agonists at least once in 2025.

Another 14% expressed interest in trying them, according to the nationally representative American Life Panel survey.

The research included 8,793 adults and examined treatment use for weight loss, diabetes, heart disease, and other chronic conditions.

5. 21% of U.S. households include a current GLP-1 user

As of May 2026, 21% of U.S. households included at least one current GLP-1 user, up from 9% in January 2025, according to PwC's analysis of Numerator data.

PwC described adoption as relatively consistent across income levels, nearly equal between men and women, and led by Generation X.

This measure counts households rather than individual patients. A household with multiple GLP-1 users is counted once, so the figure cannot be compared directly with the percentage of U.S. adults taking these medications.

6. GLP-1 prescribing more than quadrupled between 2021 and 2026

GLP-1 prescriptions among U.S. adults increased from 1,884 to 8,819 per 100,000 patients between the second quarter of 2021 and the first quarter of 2026, according to Epic Research.

The increase was driven primarily by semaglutide and tirzepatide, with prescribing expanding among adults with and without diabetes.

These figures come from Epic Cosmos, a database containing records from healthcare organizations using Epic software. They describe prescribing activity rather than the number of unique adults taking medication.

7. 30% of adults who have ever used a GLP-1 took it primarily for weight loss

Among adults who have ever taken GLP-1 medications, 30% reported weight loss as their primary reason for using them, according to KFF's fall 2025 survey.

Another 38% primarily used them for a chronic condition, such as diabetes or heart disease, while 32% reported using them for both weight loss and management of a chronic condition.

These findings show why it is important to distinguish overall GLP-1 use from use specifically intended for weight management. The same medication class is prescribed for several clinical indications.

8. 90% of Americans are aware of GLP-1 weight-loss drugs

Public awareness has reached 90% of Americans, up from 80% in 2024, indicating that these medications have entered mainstream consciousness.

Gallup measured awareness of GLP-1 medications intended specifically for weight loss.

The 2026 findings were collected from 5,065 U.S. adults between May 28 and June 5, providing a nationwide view of awareness and usage.

How GLP-1 usage has changed since 2024

Gallup's results show growth in both current and lifetime use for weight loss. The share of U.S. adults currently using GLP-1 medications for weight loss increased from 3% in 2024 to 8% in 2025 and 11% in 2026.

The share who had ever used them rose from 6% in 2024 to 12% in 2025 and 15% in 2026.

These figures come from the Gallup survey and describe U.S. adults reporting GLP-1 use specifically for weight loss.

Why GLP-1 usage estimates differ

Differences between Gallup, KFF, RAND, CDC, and PwC estimates do not necessarily indicate conflicting research. These organizations measure different populations, purposes, and periods.

Gallup's 2026 estimate of 11% reflects current GLP-1 use for weight loss among U.S. adults. KFF's 2025 estimate of 12% includes current use for diabetes and other conditions. RAND's 11.8% figure measures lifetime use for any reason.

Meanwhile, the CDC's 26.5% estimate applies only to adults with diagnosed diabetes, and PwC's 21% figure measures households containing at least one GLP-1 user.

Three distinctions matter when interpreting these findings. Current use is different from lifetime use, weight-loss use is different from treatment for all indications, and individual patients are different from households or prescriptions.

Women's GLP-1 Usage: Statistics That Matter

Women represent a substantial share of GLP-1 users, and the data reveals distinct patterns in how women approach, adopt, and experience these treatments. For telehealth platforms like Majesta Health that focus specifically on women's health, these statistics highlight both opportunity and responsibility.

9. 22% of adults aged 50 to 64 currently take a GLP-1

Current GLP-1 use was highest among adults aged 50 to 64, at 22%, according to KFF's November 2025 Health Tracking Poll.

Smaller shares of adults aged 18 to 29 (4%), 30 to 49 (11%), and 65 and older (9%) reported currently using these drugs.

KFF also found that women were more likely than men to report using GLP-1 drugs.

10. 20% of women aged 50 to 64 have used GLP-1 medications

The highest reported usage rate among the female age groups examined by RAND belongs to women between 50 and 64, where 20% have taken a GLP-1 agonist.

This compares with approximately 17% of men in the same age group, according to the study's demographic analysis.

The findings reflect lifetime experience with these medications, including treatment for weight loss and chronic health conditions.

11. 15.1% of women aged 30 to 49 have used GLP-1s

Within the 30 to 49 age group, women show 15.1% lifetime usage of GLP-1 medications, according to RAND's 2025 research.

Men in the same age group reported a 7.2% usage rate, making women more than twice as likely to have tried treatment.

The results highlight differences in medication adoption across age and sex, rather than differences in treatment effectiveness.

GLP-1 use by age and sex

RAND's findings show that the difference between women and men varies considerably across age groups.

Age groupWomen who have ever used GLP-1sMen who have ever used GLP-1s
18–294.1%2.5%
30–4915.1%7.2%
50–6420.0%16.8%
65+12.8%13.5%

Source: RAND American Life Panel*, spring 2025. Figures represent lifetime use for any indication. Differences between groups are not necessarily statistically significant.*

12. 81% of GLP-1 obesity-treatment initiators were women

Among patients starting GLP-1 treatment specifically for obesity, 81% were women, according to a pharmacy-benefit claims analysis published in 2024.

The analysis examined 3,364 commercially insured patients without diabetes who initiated treatment in 2021.

This percentage describes the study population, not the proportion of women among all GLP-1 users nationally.

13. 27.2% of women with diagnosed diabetes used GLP-1 injectables

Among women with diagnosed diabetes, 27.2% used GLP-1 injectables in 2024, according to CDC research.

The corresponding figure for men was 25.9%, with no statistically significant difference between the groups.

These statistics apply to adults with diagnosed diabetes rather than women receiving GLP-1 medications exclusively for weight management.

14. 27% of women not currently taking GLP-1s are interested in treatment

Among women not currently taking GLP-1 medications, 27% expressed interest in using them for weight loss, compared with 18% of men, according to KFF's fall 2025 survey.

Among adults who had been told by a physician within the previous five years that they were overweight or had obesity, 43% expressed interest.

These responses measure interest rather than actual prescriptions, treatment eligibility, or plans to begin medication.

What the usage data means for women

Taken together, these studies suggest that women's GLP-1 use differs substantially by age, treatment indication, and the population being measured.

Women and men with diagnosed diabetes reported similar use of injectable GLP-1 medications in CDC research. In contrast, women represented 81% of one commercially insured cohort starting treatment for obesity without diabetes.

The difference was particularly pronounced among adults aged 30 to 49 in RAND's survey. GLP-1 use was also highest overall among adults aged 50 to 64 in KFF's research, overlapping with the ages when many women experience the menopausal transition.

However, these surveys do not establish that perimenopause or menopause caused the increased use. They describe treatment patterns, not the individual reasons women sought prescriptions.

GLP-1 Usage Among People With Diabetes

While weight management has driven recent growth, GLP-1 medications originated as diabetes treatments and remain widely used for blood sugar management.

15. 26.5% of adults with diagnosed diabetes use GLP-1 injectables

Among adults with diagnosed diabetes, 26.5% used injectable GLP-1 medications to lower blood sugar or lose weight in 2024, according to CDC data.

The findings came from the National Health Interview Survey and represent medication use at the time respondents were interviewed.

The CDC report covers adults with diagnosed diabetes and does not limit its analysis exclusively to type 2 diabetes.

16. 33.3% of diabetic adults aged 50 to 64 use GLP-1 injectables

The highest usage rate by age among adults with diagnosed diabetes occurs in the 50 to 64 group, where 33.3% use GLP-1 injectables.

Usage was 25.3% among adults aged 18 to 34 and 20.8% among those aged 65 and older.

These results describe injectable medication usage in 2024, rather than lifetime exposure to GLP-1 treatments.

17. 32.4% of adults with diabetes and obesity use GLP-1 injectables

Among those with diagnosed diabetes, 32.4% with obesity used GLP-1 injectables in 2024, compared with 16.7% of those at a healthy weight.

The CDC identified an association between higher body mass index and greater GLP-1 injectable usage.

These differences reflect observed treatment patterns among adults with diabetes and do not establish why individual patients received prescriptions.

18. 57% of adults diagnosed with diabetes have ever used a GLP-1

More than half of adults with diagnosed diabetes, 57%, have ever used a GLP-1 drug, including 45% who reported currently using one.

KFF collected these findings in its October 27 to November 2, 2025, Health Tracking Poll.

These figures are based on respondents who reported a diabetes diagnosis and include GLP-1 medications taken for any indication.

GLP-1 Side Effects: What the Data Shows

Understanding side effect patterns helps set realistic expectations. These statistics reflect reported experiences across GLP-1 users generally. For guidance on managing GLP-1 side effects, working with a physician who provides ongoing support is important.

19. 52% of GLP-1 users report experiencing nausea

Nausea is the most commonly reported side effect, with 52% of users indicating they have experienced it.

RAND found that 43.2% reported mild nausea, while 8.8% classified their experiences as serious.

The survey collected self-reported side effects from adults who had ever taken GLP-1 medications.

20. 34.3% of GLP-1 users report experiencing diarrhea

Gastrointestinal effects are common, with 34.3% of adults who have used GLP-1 agonists reporting diarrhea.

Among respondents, 26.8% described this side effect as mild and 7.5% as serious.

The same RAND survey documented vomiting in 19.8% of respondents.

RAND also found that 14.4% of respondents reported mild vomiting and 5.4% described it as serious. Another 8.5% reported a hollowed-out facial appearance, including 7.4% who described it as mild and 1.1% as serious.

These findings were self-reported and covered different medications. RAND did not establish that the respondents' descriptions of serious symptoms represented medically confirmed serious adverse events.

Important safety considerations: Common gastrointestinal side effects should be distinguished from serious medication risks. FDA-approved semaglutide and tirzepatide products carry boxed warnings concerning thyroid C-cell tumors based on rodent findings. Their prescribing information also identifies contraindications involving certain thyroid cancer histories and serious risks such as pancreatitis and gallbladder problems.

Compounded preparations do not have their own FDA-approved prescribing labels, and approved-product safety data do not establish identical risks for compounded formulations.

The FDA also warns about safety concerns associated with compounded GLP-1 medications. A licensed physician should review medical history, potential contraindications, pregnancy considerations, and treatment alternatives before prescribing. Severe or persistent abdominal pain, particularly with vomiting, requires prompt medical attention.

Affordability and Cost Barriers

Cost remains a significant challenge for GLP-1 access. These statistics help explain why consumers compare medication costs and transparent pricing models. Majesta Health emphasizes pricing transparency with all-inclusive monthly pricing designed to cover physician consultation, prescribed medication, and shipping when treatment is approved.

21. 56% of GLP-1 users say these drugs were difficult to afford

More than half of adults who had ever used GLP-1 medications, 56%, reported difficulty affording these medications, including 55% of those with insurance coverage.

KFF also found that approximately one-quarter of users considered the medications very difficult to afford.

The figures describe affordability experiences among adults who had ever taken GLP-1 medications, regardless of whether they continued treatment.

22. 14% of GLP-1 users stopped treatment because of cost

Among adults who have ever used GLP-1 medications, 14% cite cost as a reason they are no longer taking treatment.

A similar share, 13%, reported stopping because of side effects, while 5% said their condition improved.

The percentages describe reasons for discontinuation among all respondents who had ever used these medications, not percentages restricted to former users.

23. 27% of GLP-1 users had insurance but paid the full cost

27% of GLP-1 users reported having health insurance but paying the full medication cost themselves.

KFF found that most insured users received at least some coverage for their GLP-1 medications.

However, having health insurance did not necessarily mean that the medication was covered or affordable for every patient.

KFF also reported that 56% of adults who had ever taken these medications found them difficult to afford, including 55% of insured users. Separately, 14% cited cost as a reason for discontinuing treatment. These percentages measure different groups and should not be added together.

24. Insured adults were three times as likely to take a GLP-1

In KFF's fall 2025 survey, 12% of insured adults reported currently taking a GLP-1, compared with 4% of uninsured adults.

This represents a threefold difference in reported current use.

The survey does not establish why insured adults reported greater use. Differences in healthcare access, prescription coverage, treatment costs, and other factors may contribute.

25. 33% of the largest employers covered GLP-1s for weight loss in 2026

Among employers with 5,000 or more workers that offered health benefits, 33% covered GLP-1 medications prescribed primarily for weight loss in 2026, according to KFF's Employer Health Benefits Survey.

Across all firms with 200 or more workers offering health benefits, 18% reported coverage.

Among firms covering these medications for weight loss, 40% required participation in a lifestyle program or meetings with a healthcare professional, such as a dietitian, case manager, or therapist.

The survey collected information from 1,937 employers between January and July 2026.

26. 13 state Medicaid programs covered GLP-1s for obesity in January 2026

As of January 2026, 13 state Medicaid programs covered GLP-1 medications for obesity under fee-for-service arrangements, according to KFF.

This represents a decline from the 16 programs identified in October 2025, reflecting changes in state coverage policies.

Medicaid coverage for obesity treatment is distinct from coverage for other medically accepted indications, such as diabetes. Coverage rules and prior authorization requirements vary by state and may change over time.

27. Medicare Part D spent $27.5 billion on GLP-1s in 2024

Gross Medicare Part D spending on GLP-1 medications reached $27.5 billion in 2024, according to KFF's analysis of federal data.

This was approximately five times the 2019 total, before accounting for manufacturer rebates. KFF estimated that rebates could reduce net spending substantially.

The same analysis found that approximately two million Medicare Part D enrollees used Ozempic in 2024, compared with fewer than 150,000 in 2019.

Traditional Medicare Part D coverage includes GLP-1 medications for certain FDA-approved indications, but generally excludes medications prescribed solely for weight loss.

However, the Medicare GLP-1 Bridge provides eligible Medicare Part D beneficiaries access to certain GLP-1 medications through a separate temporary demonstration. The program began July 1, 2026, and is scheduled to continue through December 31, 2027, with a $50 monthly copayment for eligible participants.

For more information, see Majesta's guide to Medicare and GLP-1 coverage.

Compounded GLP-1 Usage

Compounded GLP-1 medications represent a measurable segment of reported usage. Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication. For more information, see the guide to compounded semaglutide.

28. 18% of current GLP-1 users report taking compounded preparations

Compounded or custom-mixed GLP-1 medications represented 18% of current usage among adults taking GLP-1s for weight loss, according to Gallup's 2026 survey.

Brand-name prescription medications accounted for 66% of reported usage, while 13% of respondents were unsure whether they were taking a brand-name medication.

These figures reflect patients' self-reported medication categories rather than independently verified prescription or pharmacy-dispensing records. They do not establish that compounded and FDA-approved medications have equivalent effectiveness, safety, or quality.

Treatment Persistence and Long-Term Adherence

Long-term treatment persistence data reveals why ongoing support matters. These statistics underscore the importance of choosing a provider that offers continuous care, not just initial prescriptions.

Persistence rates vary according to when patients started treatment, which medications were included, and how long they were followed. Findings from different cohorts should not be interpreted as directly comparable treatment outcomes.

29. Only 14.8% of patients remained on GLP-1 treatment at two years

Persistence rates declined significantly over time, with only 14.8% of patients remaining on GLP-1 obesity treatment at the two-year mark.

The same study reported persistence rates of 47.1% at six months and 28.9% at one year.

These findings represent commercially insured adults without diabetes who initiated treatment in 2021, so they should not be generalized to every contemporary GLP-1 treatment program.

The study measured treatment persistence through pharmacy claims, counting extended gaps between prescription fills as discontinuation.

30. 8.1% of patients remained on GLP-1 treatment at three years

Prime Therapeutics followed 5,780 commercially insured adults without diabetes who initiated GLP-1 treatment for obesity between January 2021 and March 2022.

After three years, 8.1% remained on treatment, according to the analysis published in June 2025.

Persistence differed by medication, with some newer obesity-treatment medications showing higher rates than older GLP-1 products.

These findings apply to the specific treatment cohort and follow-up period. Pharmacy claims may not capture medications obtained outside the insurance system, including prescriptions paid entirely out of pocket.

31. One-year treatment persistence reached 62.6% in a later cohort

A separate Prime Therapeutics analysis found that 62.6% of patients in its early-2024 initiation cohort remained on treatment at one year.

The analysis included a larger population of commercially insured adults without diabetes and examined persistence across different initiation periods.

The researchers identified substantial differences between earlier and later treatment cohorts. Changes in medication availability, treatment practices, and patient support may have contributed, but the observational findings do not prove that any single factor caused the differences.

One-year GLP-1 treatment persistence by initiation period

Prime Therapeutics reported the following one-year persistence figures across initiation cohorts.

Initiation periodPatients remaining on treatment at one year
202133.2%
202234.1%
202340.4%
January–March 202462.6%

Source: Prime Therapeutics research*, June 2025. Commercially insured adults without diabetes. Differences in medication availability, initiation cohorts, and follow-up characteristics limit direct comparisons.*

These findings should not be used to predict how long any individual patient will continue treatment. A prescribing physician should assess treatment response, side effects, medical appropriateness, and the need for continued monitoring.

Telehealth Access and Support Gaps

The way patients access GLP-1 medications is shifting, with telehealth playing an increasing role. Yet significant gaps remain in the support consumers receive.

32. 17% of GLP-1 users obtained medications through online providers

Among adults who had ever taken GLP-1 medications, 17% obtained them from an online provider or website, according to KFF.

Most respondents, 76%, obtained treatment through a primary healthcare provider or specialist.

The survey also found that 9% had obtained GLP-1 medications through a medical spa or aesthetic medical center.

These categories may overlap because respondents could report obtaining medications through more than one type of provider.

33. 7% of GLP-1 users get or plan to get prescriptions through telehealth

PwC found that 7% of GLP-1 users said they received or planned to receive prescriptions through telehealth.

Most respondents, 63%, identified primary care physicians as their prescription source, while 10% identified specialists.

Unlike KFF's retrospective prescription-source figures, PwC's measure includes both existing and planned prescription channels. Its survey focused on current, former, and prospective GLP-1 users rather than a representative sample of all U.S. adults.

34. Roughly 85% of current users say companies are falling short

According to PwC's 2026 consumer research, roughly 85% of current users say companies are falling short in meeting their needs.

The research examines consumer-facing brands and wellness services rather than directly measuring satisfaction with prescribing physicians.

PwC surveyed 3,089 current, former, and prospective GLP-1 users to understand medication-related behaviors and support needs. The findings should not be interpreted as representative of all U.S. consumers.

35. Only 23% of GLP-1 users feel well-supported by wellness platforms

PwC found that only 23% feel well-supported by wellness platforms offering nutrition, fitness, mental health, and related services.

The survey also found that nearly a quarter of current users reported figuring out their routines independently.

These findings describe support from consumer wellness platforms and should not be interpreted as evidence that most prescribing healthcare professionals provide inadequate medical care.

36. 41% of current GLP-1 users have never participated in strength training

Among current GLP-1 users in PwC's 2026 survey, 41% reported never doing strength training.

Another 21% reported increasing their strength-training frequency since starting GLP-1 medication, while 17% reported decreasing it.

Changes in aerobic activity were also common. Approximately 36% reported increasing activities such as walking, running, cycling, or swimming, compared with 16% who reported doing these activities less frequently.

These findings highlight the importance of discussing muscle preservation, nutrition, and suitable physical activity with a healthcare professional during weight management.

Majesta's guides to GLP-1 muscle preservation and protein needs provide additional educational information.

What These Statistics Mean for Women Seeking GLP-1 Treatment

The data paints a clear picture: GLP-1 medications are increasingly mainstream, women represent a substantial share of users, and significant barriers remain around cost and support.

For women considering GLP-1 treatment, these statistics suggest several priorities:

  • Look for transparent pricing. With 56% of users, including 55% of those with insurance, saying the medications were difficult to afford, all-inclusive pricing models can reduce uncertainty about hidden fees, separate membership charges, and surprise costs.
  • Prioritize ongoing support. Given that many users report insufficient wellness support and treatment persistence can decline over time, choosing a provider with built-in check-ins and care team access can be useful for long-term treatment management.
  • Understand compounded medication options. With 18% of current users reporting compounded preparations, patients should understand the regulatory and safety differences between compounded products and FDA-approved medications before considering treatment.
  • Consider telehealth for convenience. As 17% of users have obtained medications online, telehealth platforms can provide an additional access option while maintaining appropriate physician oversight.
  • Ask about muscle preservation. With 41% of surveyed current users reporting no strength training, discussing suitable resistance exercise and adequate nutrition may help support long-term metabolic health.

Majesta Health publishes transparent plan pricing. As confirmed in the company's November 16, 2026 update, the Essential plan is $159 for the first month, then $289 per month, and the Performance plan is $269 for the first month, then $399 per month. The planned Express plan features compounded Tirzepatide LPT® Chewable Tablets, with proposed pricing of $249 for the first approved 30-day care cycle and $339 per approved 30-day care cycle thereafter.

Pricing includes physician consultation, prescribed compounded medication, shipping, and ongoing support, subject to physician approval. Enrollment had not opened as of that update.

Physician-Guided GLP-1 Care With Majesta Health

The statistics show that GLP-1 medications are becoming increasingly common, particularly among women. However, affordability, side effects, and long-term treatment persistence remain significant challenges. Choosing the right provider means finding more than medication. It means finding care that supports your individual health needs.

Majesta Health is a LegitScript-certified telehealth platform designed specifically for women seeking physician-guided GLP-1 weight management, with transparent pricing and ongoing clinical support.

Here's what makes Majesta Health worth considering:

  • Women-centered care: The platform focuses on women's weight management, including concerns related to perimenopause, menopause, and metabolic health.
  • Transparent monthly pricing: Essential features compounded Semaglutide/Glycine/B12 Injection at $159 for the first month and $289/month thereafter. Performance features compounded Tirzepatide/Glycine/B12 Injection at $269 for the first month and $399/month thereafter. The planned Express plan features compounded Tirzepatide LPT® Chewable Tablets, with proposed pricing of $249 for the first approved 30-day care cycle and $339 per approved 30-day care cycle thereafter. Express is not yet available for enrollment. The plan prices include a $20 physician consultation, medication when prescribed, and shipping, without separate membership fees. These details reflect the November 17, 2026 company-confirmed update.
  • Licensed medical oversight: Independent, U.S.-licensed physicians evaluate medical history, determine treatment appropriateness, and make prescribing decisions. Majesta does not itself prescribe or dispense medications.
  • Ongoing treatment support: The planned injection plans include monthly physician check-ins, care-team messaging, and 2-day shipping, with pharmacy preparation time handled separately.
  • Named pharmacy partners: Majesta works with Belmar Pharma Solutions and Strive Pharmacy. The dispensing arrangements for individual prescriptions are determined separately.

As of November 16, 2026, enrollment had not opened. Prospective patients could complete an assessment and join early access without payment or placing a medication order. Nothing is charged until an independent physician approves treatment. The platform does not offer FDA-approved brand-name medications, menopause hormone therapy, or insurance billing.

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication.

Whether you're exploring GLP-1 treatment for the first time or looking for a more supportive care experience, Majesta Health connects prospective patients with independent physicians who review their histories and decide whether treatment is appropriate once enrollment opens.

Start your assessment to join early access. It takes approximately two minutes, requires no payment, and does not guarantee treatment or a prescription.

Before you change anything

Discuss your medical history, current medications, pregnancy plans, and potential treatment risks with a licensed physician before considering GLP-1 medication. Do not independently start, stop, or change a prescription based on usage statistics or other people's experiences.

When to get help right away

Seek urgent medical attention for severe or persistent abdominal pain, particularly with vomiting. Call 911 for chest pain, trouble breathing, fainting, or signs of a severe allergic reaction. Contact your prescribing clinician promptly concerning side effects or symptoms that interfere with daily activities.

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It does not recommend starting, stopping or changing any medicine.

Sources checked November 17, 2026.

Frequently Asked Questions

What percentage of GLP-1 users are women?

Women represent a substantial share of GLP-1 users, although the proportion varies by treatment indication and population. Among patients starting GLP-1 treatment specifically for obesity, 81% were women in one commercially insured cohort. Among women aged 50 to 64, one in five reported having used these medications in RAND's 2025 survey.

How many people stop taking GLP-1 medications and why?

Long-term persistence varies by patient population and treatment period. Only 14.8% of patients in a commercially insured obesity-treatment cohort remained on GLP-1 therapy at two years. A separate analysis found that 8.1% of an earlier treatment cohort remained on medication at three years, while a later cohort showed substantially higher one-year persistence. Separately, KFF found that 14% of adults who had ever used GLP-1 medications stopped because of cost, while 13% stopped because of side effects.

What percentage of GLP-1 users take compounded medications?

Compounded GLP-1 preparations account for 18% of current reported usage among adults taking these medications for weight loss in Gallup's 2026 survey.Compounded medications are not FDA-approved as final products, and their reported usage does not establish equivalence with FDA-approved medications.

How common are GLP-1 side effects?

Gastrointestinal side effects are frequently reported. Approximately 52% of users reported nausea, 34.3% reported diarrhea, and 19.8% reported vomiting in RAND's 2025 survey. Among respondents who experienced these side effects, most described them as mild rather than serious. These self-reported figures cover different medications and should not be applied to a specific compounded formulation. Physician oversight can help patients identify and manage treatment-related symptoms.

Does insurance cover GLP-1 medications for weight loss?

Coverage varies according to the insurance plan, medication, and prescribing indication. In 2026, 33% of employers with 5,000 or more workers offering health benefits covered GLP-1 medications primarily for weight loss, according to KFF's employer survey. As of January 2026, 13 state Medicaid programs covered GLP-1 medications for obesity under fee-for-service arrangements. Eligible Medicare Part D beneficiaries may also access certain medications through the temporary Medicare GLP-1 Bridge program.

Sources

  1. 1.GLP-1 Usage Reaches New High. Gallup National Health and Well-Being Index. Originally published July 7, 2026; updated September 8, 2026. Original survey research · Gallup · accessed
  2. 2.KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. Published November 14, 2025. Original survey research · KFF · accessed
  3. 3.New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. Published August 6, 2025. Original research report. RAND American Life Panel · RAND Corporation · accessed
  4. 4.GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024. NCHS Data Brief No. 537. Published August 2025 · CDC, National Center for Health Statistics · accessed
  5. 5.GLP-1 Treatment Adherence: Year-Two Real-World Analysis of GLP-1 Obesity Treatment Adherence and Persistency. Published July 10, 2024 · Prime Therapeutics · accessed
  6. 6.Three-Year Treatment Persistence. Published June 25, 2025. Original pharmacy claims analysis · Prime Therapeutics · accessed
  7. 7.GLP-1 Consumer Trends. Published June 22, 2026. Original consumer survey and Numerator household analysis · PwC US · accessed
  8. 8.GLP-1 Prescribing Trends. Published May 21, 2026. Original Epic Cosmos analysis · Epic Research · accessed
  9. 9.2026 Employer Health Benefits Survey. Published October 2026. Original employer survey · KFF · accessed
  10. 10.Medicaid Coverage of GLP-1s. Published January 16, 2026. Original Medicaid policy analysis · KFF · accessed
  11. 11.Medicare GLP-1 Spending. Published January 30, 2026. Analysis of CMS Medicare Part D data · KFF · accessed
  12. 12.Medicare GLP-1 Bridge. Program information for July 2026–December 2027 · Centers for Medicare & Medicaid Services · accessed
  13. 13.KFF GLP-1 Interest Poll. Published November 2025. Original survey research · KFF · accessed
  14. 14.FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. Medication safety and regulatory guidance · U.S. Food and Drug Administration · accessed
  15. 15.Zepbound Prescribing Information. 2026 prescribing information · U.S. Food and Drug Administration · accessed
  16. 16.Majesta Health Pricing. Official pricing and treatment information · Majesta Health · accessed
  17. 17.About Majesta Health. Official company information and mission · Majesta Health · accessed
  18. 18.Majesta Health Care Team. Official physician and care team information · Majesta Health · accessed

Ready to Join Early Access?

Join the early access list and we will email you when enrollment opens.

Start Your Assessment